Replies to post #213839 on Biotech Values

[DewDiligence]

EpiVax Oncology (private) is another:

http://www.prnewswire.com/news-releases/epivax-launches-precision-cancer-immunotherapy-venture-epivax-oncology-300525002.html

[biocqr]

ADXS > new corp presentation...

http://ir.advaxis.com/all-sec-filings/content/0001493152-17-010879/ex99-1.htm

[DewDiligence]

(ADXS)—ADRO is yet another neoantigen competitor:

https://globenewswire.com/news-release/2017/09/27/1133689/0/en/Aduro-Biotech-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-Personalized-Immunotherapy-pLADD-Based-on-Proprietary-Neoantigen-Technology.html

The single indication in ADRO’s phase-1 trial is second-line colorectal cancer.

ADXS NEO’s phase-1, which has not yet enrolled any patients (#msg-134670005), will (purportedly) be tested in NSCLC, H&N cancer, and CRC.